AVAC and Access Bridge today issued a global call to action urging governments, donors, manufacturers, implementers, and advocates to work toward a bold but achievable goal: reaching at least three ...

Challenges and scientific progress took center stage at the World Health Summit in Berlin, the UN adopted a new pandemic preparedness declaration, concerns continue over the proposed US-funded ...

This Financial Times webinar, hosted in partnership with ViiV Healthcare, will bring together policymakers, funders, researchers, philanthropies and industry leaders to explore how to keep medical ...

US Government’s Opportunity to Reach At Least Three Million with LEN by 2027 AVAC’s new publication, Now What with Injectable LEN for PrEP: How to Translate Ambition into Accelerated Delivery and ...

In July, Merck announced licensing agreements with seven manufacturers for generic production of its HIV drug alimatravir, though access and equity concerns remain. As AVAC’s Executive Director ...

Seventeen countries are hosting sites for the Phase III efficacy trials of a monthly PrEP pill, called MK-8527, now known as alimatravir, being developed by Merck (also known as MSD outside of the US ...

The term autonomous means that a person can make his or her own decisions about what to do and what to agree to. Researchers must respect that individuals should make their own informed decisions ...

Youth Engage Stay up-to-date! Subscribe Subscribe ...

The 2026 US HIV Cure Academy brought skilled advocates and leading HIV cure researchers together for three days of learning and engagement. “We may not have a cure, but one thing is sure, we have the ...

“The Trump administration’s freeze on foreign assistance funding is dangerous and illegal,” said Public Citizen attorney Lauren Bateman, the lead lawyer on the case. “When programs like the ones run ...

New York City, June 20, 2024 – AVAC welcomes the groundbreaking results of the PURPOSE 1 HIV prevention study among adolescent girls and young women in South Africa and Uganda. Preliminary safety and ...